WO1997021808A1 - Modified vegf antisense oligonucleotides - Google Patents
Modified vegf antisense oligonucleotides Download PDFInfo
- Publication number
- WO1997021808A1 WO1997021808A1 PCT/US1996/019320 US9619320W WO9721808A1 WO 1997021808 A1 WO1997021808 A1 WO 1997021808A1 US 9619320 W US9619320 W US 9619320W WO 9721808 A1 WO9721808 A1 WO 9721808A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- seq
- oligonucleotide
- vegf
- oligonucleotides
- nucleic acid
- Prior art date
Links
- 239000000074 antisense oligonucleotide Substances 0.000 title description 20
- 238000012230 antisense oligonucleotides Methods 0.000 title description 20
- 108020000948 Antisense Oligonucleotides Proteins 0.000 title description 16
- 101100372758 Danio rerio vegfaa gene Proteins 0.000 title 1
- 101150030763 Vegfa gene Proteins 0.000 title 1
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 163
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims abstract description 81
- 150000007523 nucleic acids Chemical class 0.000 claims abstract description 49
- 108020004707 nucleic acids Proteins 0.000 claims abstract description 41
- 102000039446 nucleic acids Human genes 0.000 claims abstract description 41
- 230000014509 gene expression Effects 0.000 claims abstract description 33
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 25
- 230000000295 complement effect Effects 0.000 claims abstract description 7
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims abstract 6
- 238000000034 method Methods 0.000 claims description 35
- 125000002652 ribonucleotide group Chemical group 0.000 claims description 14
- -1 phosphate ester Chemical class 0.000 claims description 12
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 claims description 11
- 102000058223 human VEGFA Human genes 0.000 claims description 11
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 11
- 230000002401 inhibitory effect Effects 0.000 claims description 10
- 229910019142 PO4 Inorganic materials 0.000 claims description 8
- 230000004048 modification Effects 0.000 claims description 8
- 238000012986 modification Methods 0.000 claims description 8
- 239000010452 phosphate Substances 0.000 claims description 8
- PTMHPRAIXMAOOB-UHFFFAOYSA-L phosphoramidate Chemical compound NP([O-])([O-])=O PTMHPRAIXMAOOB-UHFFFAOYSA-L 0.000 claims description 6
- 125000005600 alkyl phosphonate group Chemical group 0.000 claims description 4
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 claims description 3
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 2
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 2
- NAGJZTKCGNOGPW-UHFFFAOYSA-K dioxido-sulfanylidene-sulfido-$l^{5}-phosphane Chemical compound [O-]P([O-])([S-])=S NAGJZTKCGNOGPW-UHFFFAOYSA-K 0.000 claims description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 abstract description 69
- 206010029113 Neovascularisation Diseases 0.000 abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 17
- 230000033115 angiogenesis Effects 0.000 abstract description 9
- 102000009524 Vascular Endothelial Growth Factor A Human genes 0.000 description 74
- 210000004027 cell Anatomy 0.000 description 39
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 29
- 230000000692 anti-sense effect Effects 0.000 description 28
- 239000002299 complementary DNA Substances 0.000 description 24
- 239000002773 nucleotide Substances 0.000 description 22
- 125000003729 nucleotide group Chemical group 0.000 description 21
- 241000699670 Mus sp. Species 0.000 description 16
- 238000011282 treatment Methods 0.000 description 15
- 206010021143 Hypoxia Diseases 0.000 description 13
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 13
- 210000001525 retina Anatomy 0.000 description 13
- 208000007135 Retinal Neovascularization Diseases 0.000 description 12
- 108091028664 Ribonucleotide Proteins 0.000 description 12
- 108010082117 matrigel Proteins 0.000 description 12
- 239000002336 ribonucleotide Substances 0.000 description 12
- 201000010099 disease Diseases 0.000 description 11
- 108020004999 messenger RNA Proteins 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 206010028980 Neoplasm Diseases 0.000 description 9
- 108091028043 Nucleic acid sequence Proteins 0.000 description 9
- 206010038933 Retinopathy of prematurity Diseases 0.000 description 9
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 230000007954 hypoxia Effects 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 229910052760 oxygen Inorganic materials 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 9
- 201000004569 Blindness Diseases 0.000 description 8
- 206010012689 Diabetic retinopathy Diseases 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 239000007924 injection Substances 0.000 description 8
- 238000002347 injection Methods 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 7
- 208000005017 glioblastoma Diseases 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 239000005547 deoxyribonucleotide Substances 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 102000004169 proteins and genes Human genes 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- GVPFVAHMJGGAJG-UHFFFAOYSA-L cobalt dichloride Chemical compound [Cl-].[Cl-].[Co+2] GVPFVAHMJGGAJG-UHFFFAOYSA-L 0.000 description 5
- 230000006378 damage Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000007920 subcutaneous administration Methods 0.000 description 5
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 4
- WZUVPPKBWHMQCE-UHFFFAOYSA-N Haematoxylin Chemical compound C12=CC(O)=C(O)C=C2CC2(O)C1C1=CC=C(O)C(O)=C1OC2 WZUVPPKBWHMQCE-UHFFFAOYSA-N 0.000 description 4
- 102100034343 Integrase Human genes 0.000 description 4
- 101710203526 Integrase Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 4
- 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 4
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical group CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 206010064930 age-related macular degeneration Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 125000004432 carbon atom Chemical group C* 0.000 description 4
- 125000003636 chemical group Chemical group 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 125000005843 halogen group Chemical group 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 230000001146 hypoxic effect Effects 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 238000007918 intramuscular administration Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 208000002780 macular degeneration Diseases 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 235000000346 sugar Nutrition 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229910021580 Cobalt(II) chloride Inorganic materials 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- 208000010412 Glaucoma Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 229930040373 Paraformaldehyde Natural products 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- PYMYPHUHKUWMLA-LMVFSUKVSA-N Ribose Natural products OC[C@@H](O)[C@@H](O)[C@@H](O)C=O PYMYPHUHKUWMLA-LMVFSUKVSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 125000000217 alkyl group Chemical group 0.000 description 3
- HMFHBZSHGGEWLO-UHFFFAOYSA-N alpha-D-Furanose-Ribose Natural products OCC1OC(O)C(O)C1O HMFHBZSHGGEWLO-UHFFFAOYSA-N 0.000 description 3
- 125000003277 amino group Chemical group 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 125000002637 deoxyribonucleotide group Chemical group 0.000 description 3
- 208000035475 disorder Diseases 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009396 hybridization Methods 0.000 description 3
- 230000000222 hyperoxic effect Effects 0.000 description 3
- 238000007901 in situ hybridization Methods 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 201000003142 neovascular glaucoma Diseases 0.000 description 3
- 229920002866 paraformaldehyde Polymers 0.000 description 3
- 150000004713 phosphodiesters Chemical class 0.000 description 3
- 230000004962 physiological condition Effects 0.000 description 3
- 229920000642 polymer Polymers 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000002207 retinal effect Effects 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000013518 transcription Methods 0.000 description 3
- 230000035897 transcription Effects 0.000 description 3
- 238000012384 transportation and delivery Methods 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 230000004393 visual impairment Effects 0.000 description 3
- ASJSAQIRZKANQN-CRCLSJGQSA-N 2-deoxy-D-ribose Chemical group OC[C@@H](O)[C@@H](O)CC=O ASJSAQIRZKANQN-CRCLSJGQSA-N 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- HMFHBZSHGGEWLO-SOOFDHNKSA-N D-ribofuranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H]1O HMFHBZSHGGEWLO-SOOFDHNKSA-N 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 206010038848 Retinal detachment Diseases 0.000 description 2
- 206010038935 Retinopathy sickle cell Diseases 0.000 description 2
- 239000008156 Ringer's lactate solution Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000003118 aryl group Chemical group 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037765 diseases and disorders Diseases 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000004438 eyesight Effects 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012737 fresh medium Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000035876 healing Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 238000002642 intravenous therapy Methods 0.000 description 2
- 239000010410 layer Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000000386 microscopy Methods 0.000 description 2
- 238000010369 molecular cloning Methods 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 210000004940 nucleus Anatomy 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000012188 paraffin wax Substances 0.000 description 2
- 230000001575 pathological effect Effects 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000008300 phosphoramidites Chemical class 0.000 description 2
- 230000000649 photocoagulation Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000020874 response to hypoxia Effects 0.000 description 2
- 230000004264 retinal detachment Effects 0.000 description 2
- 208000004644 retinal vein occlusion Diseases 0.000 description 2
- 125000000548 ribosyl group Chemical group C1([C@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000010189 synthetic method Methods 0.000 description 2
- 238000007910 systemic administration Methods 0.000 description 2
- 238000012385 systemic delivery Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- 229950004616 tribromoethanol Drugs 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
- ALSQUSUPDQPCQY-UHFFFAOYSA-N (methoxyamino)phosphonous acid Chemical compound CONP(O)O ALSQUSUPDQPCQY-UHFFFAOYSA-N 0.000 description 1
- BCOSEZGCLGPUSL-UHFFFAOYSA-N 2,3,3-trichloroprop-2-enoyl chloride Chemical compound ClC(Cl)=C(Cl)C(Cl)=O BCOSEZGCLGPUSL-UHFFFAOYSA-N 0.000 description 1
- 238000012232 AGPC extraction Methods 0.000 description 1
- 241000766754 Agra Species 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 238000012286 ELISA Assay Methods 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 102100031780 Endonuclease Human genes 0.000 description 1
- 108010042407 Endonucleases Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 208000003098 Ganglion Cysts Diseases 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 206010058490 Hyperoxia Diseases 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 108091026898 Leader sequence (mRNA) Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 208000001140 Night Blindness Diseases 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000019483 Peanut oil Nutrition 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108010021757 Polynucleotide 5'-Hydroxyl-Kinase Proteins 0.000 description 1
- 102000008422 Polynucleotide 5'-hydroxyl-kinase Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 206010036590 Premature baby Diseases 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038934 Retinopathy proliferative Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000005400 Synovial Cyst Diseases 0.000 description 1
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000004423 acyloxy group Chemical group 0.000 description 1
- 238000007792 addition Methods 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001772 anti-angiogenic effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000003613 bile acid Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009395 breeding Methods 0.000 description 1
- 230000001488 breeding effect Effects 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- BPKIGYQJPYCAOW-FFJTTWKXSA-I calcium;potassium;disodium;(2s)-2-hydroxypropanoate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].C[C@H](O)C([O-])=O BPKIGYQJPYCAOW-FFJTTWKXSA-I 0.000 description 1
- BMLSTPRTEKLIPM-UHFFFAOYSA-I calcium;potassium;disodium;hydrogen carbonate;dichloride;dihydroxide;hydrate Chemical compound O.[OH-].[OH-].[Na+].[Na+].[Cl-].[Cl-].[K+].[Ca+2].OC([O-])=O BMLSTPRTEKLIPM-UHFFFAOYSA-I 0.000 description 1
- 150000004657 carbamic acid derivatives Chemical class 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 230000004456 color vision Effects 0.000 description 1
- 239000003636 conditioned culture medium Substances 0.000 description 1
- 210000004087 cornea Anatomy 0.000 description 1
- 238000000315 cryotherapy Methods 0.000 description 1
- 125000004093 cyano group Chemical group *C#N 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000008356 dextrose and sodium chloride injection Substances 0.000 description 1
- 239000008355 dextrose injection Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- NAGJZTKCGNOGPW-UHFFFAOYSA-N dithiophosphoric acid Chemical class OP(O)(S)=S NAGJZTKCGNOGPW-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000000799 fluorescence microscopy Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000013546 insoluble monolayer Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 238000002647 laser therapy Methods 0.000 description 1
- 238000013532 laser treatment Methods 0.000 description 1
- 239000004973 liquid crystal related substance Substances 0.000 description 1
- 238000012153 long-term therapy Methods 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 208000018769 loss of vision Diseases 0.000 description 1
- 231100000864 loss of vision Toxicity 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- ZQAUNTSBAZCVIO-UHFFFAOYSA-N methoxyphosphonamidic acid Chemical compound COP(N)(O)=O ZQAUNTSBAZCVIO-UHFFFAOYSA-N 0.000 description 1
- YACKEPLHDIMKIO-UHFFFAOYSA-N methylphosphonic acid Chemical compound CP(O)(O)=O YACKEPLHDIMKIO-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 230000001293 nucleolytic effect Effects 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 229940124276 oligodeoxyribonucleotide Drugs 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000000312 peanut oil Substances 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 150000002972 pentoses Chemical group 0.000 description 1
- 210000003668 pericyte Anatomy 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000005043 peripheral vision Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 235000020030 perry Nutrition 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 150000003014 phosphoric acid esters Chemical class 0.000 description 1
- 210000000608 photoreceptor cell Anatomy 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 description 1
- 230000035752 proliferative phase Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000000844 retinal pigment epithelial cell Anatomy 0.000 description 1
- 230000004233 retinal vasculature Effects 0.000 description 1
- 210000001210 retinal vessel Anatomy 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008354 sodium chloride injection Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000010186 staining Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 230000003074 vasoproliferative effect Effects 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
- 229960002555 zidovudine Drugs 0.000 description 1
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
Definitions
- This invention relates to vascular endothelial growth factor. More specifically, this invention relates to oligonucleotides specific for vascular endothelial growth factor nucleic acid and useful treatment of disorders that are associated with neovascularization and angiogenesis .
- Neovascular diseases of the retina such as diabetic retinopathy, retinopathy of prematurity, and age-related macular degeneration are a major cause of blindness in the United States and the world, yet the biochemical events responsible for these processes have not been fully elucidated.
- Diabetic retinopathy is the leading cause of blindness among working age adults (20-64) in the United States (Foster in Harrison 's Principles of Internal Medicine (Isselbacher et al . , eds.) McGraw-Hill, Inc., New York (1994) pp. 1994-1995) .
- the retinal vessels undergo changes that result in not only leaky vessels but also vessel drop out resulting in retinal hypoxia.
- panretinal laser photocoagulation PRP
- panretinal laser photocoagulation a treatment for proliferative diabetic retinopathy
- complications can occur from panretinal laser photocoagulation such as foveal burns, hemorrhaging, retinal detachment, and choroidal vessel growth.
- other untoward effects of this treatment are decreased peripheral vision, decreased night vision, and changes in color perception (Am. J. Ophthalmol. (1976) 81:383-
- ROP Retinopathy of prematurity
- Age related macular degeneration is one of the leading causes of blindness in older adults in the United States, and may account for up to 30% of all bilateral blindness among Caucasian Americans (Anonymous (1994) Prevent Blindness America ) .
- This disease is characterized by loss of central vision, usually in both eyes, due to damage to retinal pigment epithelial cells which provide physiological support to the light sensitive photoreceptor cells of the retina. In most cases there is currently no effective treatment. In approximately 20% of exudative cases that are diagnosed early, laser treatment can prevent further loss of vision; however, this effect is temporary (Bressler et al . , Principles and Practices of Ophthalmology (eds. Albert and Jakobiac), W.B.
- Ocular neovascularization is also the underlying pathology in sickle cell retinopathy, neovascular glaucoma, retinal vein occlusion, and other hypoxic diseases .
- These eye diseases as well as other pathological states associated with neovascularization appear to have hypoxia as a common factor (Knighton et al . (1983) Science 221:1283-1285; Folkman et al . (1987) Science 235:442-446; Klagsbrun et al. (1991) Ann. Rev. Physiol. 53:217-239; Miller et al . ( 1 93 ) Principles and Practice of Ophthalmology, W.B.
- retinal neovascularization has been hypothesized to be the result of a "vasoformative factor" which is released by the retina in response to hypoxia (Michaelson (1948) Trans. Ophthalmol. Soc. U. K. 68:137-
- VEGF/VPF Vascular endothelial growth factor/vascular permeability factor
- VEGF in normal tissues is relatively low.
- VEGF appears to play a principle role in many pathological states and processes related to neovascularization. Regulation of VEGF expression in tissues affected by the various conditions described above could therefore be key in treatment or preventative therapies associated with hypoxia.
- antisense oligonucleotides New chemotherapeutic agents termed "antisense oligonucleotides" have been developed which are capable of modulating cellular and foreign gene expression (see, Zamecnik et al . (1978) Proc. Natl. Acad. Sci. (USA) 75:280-284) . Without being limited to any theory or mechanism, it is generally believed that the activity of antisense oligonucleotides depends on the binding of the oligonucleotide to the target nucleic acid (e.g.
- VEGF-specific antisense oligonucleotides have been developed (Uchida et al . (1995) Antisense Res. &
- the present invention provides novel synthetic oligonucleotides specific nucleotides 58 to 90 of the VEGF gene which can reduce the hypoxia-induced expression of VEGF mRNA and protein. This information has been exploited to develop the present invention which includes VEGF- specific oligonucleotides, pharmaceutical formulation, and methods of reducing the expression of VEGF mRNA and protein.
- the invention provides a synthetic oligonucleotide complementary to a nucleic acid specific for human vascular endothelial growth factor.
- This oligonucleotide has a nucleic acid sequence set forth in the Sequence Listing as SEQ ID NOS:2-16.
- synthetic oligonucleotide refers to chemically synthesized polymers of nucleotides covalently attached via at least one 5' to 3' internucleotide linkage. In some embodiments, these oligonucleotides contain at least one deoxyribonucleotide, ribonucleotide, or both deoxyribonucleotides and ribonucleotides . In another embodiment, the synthetic oligonucleotides used in the methods of the invention are from about 15 to about 30 nucleotides in length. In preferred embodiments, these oligonucleotides contain from about 16 to 29 nucleotides .
- oligonucleotide sequence that is complementary to a genomic region or an RNA molecule transcribed therefrom is intended to mean an oligonucleotide that binds to the nucleic acid sequence under physiological conditions, e.g., by Watson-Crick base pairing (interaction between oligonucleotide and single-stranded nucleic acid) or by Hoogsteen base pairing (interaction between oligonucleotide and double-stranded nucleic acid) or by any other means including in the case of a oligonucleotide binding to RNA, causing pseudoknot formation. Binding by Watson-Crick or Hoogsteen base pairing under physiological conditions is measured as a practical matter by observing interference with the function of the nucleic acid sequence.
- the synthetic oligonucleotide of the invention are modified in a number of ways without compromising their ability to hybridize to nucleotide sequences contained within the mRNA for VEGF.
- modified oligonucleotide describes an oligonucleotide in which at least two of its nucleotides are covalently linked via a synthetic linkage, i.e., a linkage other than a phosphodiester linkage between the 5 ' end of one nucleotide and the 3 ' end of another nucleotide in which the 5 ' nucleotide phosphate has been replaced with any number of chemical groups.
- At least one internucleotide linkage of the oligonucleotide is an alkylphosphonate, phosphorothioate, phosphorodithioate, phosphate ester, alkylphosphonothioate, phosphoramidate, carbamate, carbonate, phosphate triester, acetamidate, and/or carboxymethyl ester.
- modified oligonucleotide also encompasses oligonucleotides having at least one nucleotide with a modified base and/or sugar, such as a 2 ' -O-substituted ribonucleotide.
- 2 ' -O-substituted means substitution of the 2 ' position of the pentose moiety with an -O- lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl or allyl group having 2 - 6 carbon atoms, wherein such alkyl, aryl or allyl group may be unsubstituted or may be substituted, e.g.
- the oligonucleotides of the invention include four or five ribonucleotides 2 ' -O-alkylated at their 5 ' terminus (i.e.
- the nucleotides of the synthetic oligonucleotides are linked by a or at least one phosphorothioate internucleotide linkage.
- the phosphorothioate linkages may be mixed R ⁇ and S p enantiomers, or they may be stereoregular or substantially stereoregular in either R p or S p form (see Iyer et al .
- the invention provides a method of inhibiting VEGF expression.
- nucleic acid specific for VEGF is contacted with an oligonucleotide of the invention.
- nucleic acid encompasses a genomic region or an RNA molecule transcribed therefrom.
- the nucleic acid is mRNA.
- oligonucleotides used in accordance with this invention depends on the hybridization of the oligonucleotide to the target nucleic acid (e.g. to at least a portion of a genomic region, gene or mRNA transcript thereof) , thus disrupting the function of the target.
- target nucleic acid e.g. to at least a portion of a genomic region, gene or mRNA transcript thereof
- a preferred oligonucleotide used in accordance with the invention is capable of forming a stable duplex (or triplex in the Hoogsteen pairing mechanism) with the target nucleic acid; activate RNase H thereby causing effective destruction of the target RNA molecule, and in addition is capable of resisting nucleolytic degradation (e.g. endonuclease and exonuclease activity) in vivo .
- nucleolytic degradation e.g. endonuclease and exonuclease activity
- a pharmaceutical composition comprising at least one synthetic oligonucleotide of claim 1 in a physiologically acceptable carrier.
- compositions capable of inhibiting neovascularization and thus are useful in the methods of the invention.
- compositions include a synthetic oligonucleotide of the present invention which specifically inhibits the expression of vascular endothelial growth factor and a physiologically and/or pharmaceutically acceptable carrier.
- pharmaceutically acceptable means a non-toxic material that does not interfere with the effectiveness of the biological activity of the active ingredient (s) .
- physiologically acceptable refers to a non-toxic material that is compatible with a biological system such as a cell, cell culture, tissue, or organism.
- Another aspect of the invention is assessment of the role of VEGF in neovascularization and angiogenesis associated with disease states.
- FIG. 1 is a schematic representation of the regions of the VEGF cDNA sequence that are targeted by oligonucleotides of the invention
- FIG. 2 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3-I and H3-J to inhibit VEGF expression induced by cobalt chloride;
- FIG. 3 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3-D H3-E, H3-F to inhibit VEGF expression induced by cobalt chloride;
- FIG. 4 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3-G and H3-H to inhibit VEGF expression induced by cobalt chloride;
- FIG. 5 is a graphic representation of ELISA results demonstrating the ability of oligonucleotides H3 and H3-I to inhibit VEGF expression induced by cobalt chloride in M21 human me1anoma cells in vitr ;
- H3-K all 2 ' -O- methylated phosphorothioate ribonucleotides
- H3-L five 5' 2 ' -O-alkylated phosphorothioate ribonucleotides, the remainder, phosphorothioate deoxyribonucleotides
- H3-M five 3 1 ' -O-alkylated phosphorothioate ribonucleotides, the remainder, phosphorothioate deoxyribonucleotides
- H3-N five 3 ' 2 ' -O-alkylated phosphorothioate ribonucleotides, five 5 1 2 ' -O-alkylated phosphorothioate ribonucleotides, and the remainder,
- the present invention provides synthetic antisense oligonucleotides specific for VEGF nucleic acid which are useful in treating diseases and disorders associated with neovascularization and angiogenesis, including retinal neovascularization.
- Antisense oligonucleotide technology provides a novel approach to the inhibition of gene expression (see generally, Agrawal (1992) Trends in Biotech. 10:152-158; Wagner (1994) Nature 372:333-335; and Stein et al . (1993) Science 261:1004-1012) .
- antisense oligonucleotide By binding to the complementary nucleic acid sequence (the sense strand) , antisense oligonucleotide are able to inhibit splicing and translation of RNA. In this way, antisense oligonucleotides are able to inhibit protein expression.
- Antisense oligonucleotides have also been shown to bind to genomic DNA, forming a triplex, and inhibit transcription.
- VEGF coding region is comprised of eight axons (Tischer et al (1994) I Biol Chem 266:11947-11954) Three VEGF transcripts, 121, 165, and 189 ammo acids long, have been observed, suggesting that an alternative splicing mechanism is involved (Leung et al .
- the oligonucleotides of the invention are directed to any portion of the VEGF nucleic acid sequence that effectively acts as a target for inhibiting VEGF expression.
- the sequence of the gene encoding VEGF has been reported mice (Claffey et al . , ibid. ) and for humans (Tischer et al . , ibid. ) . These targeted regions of the VEGF gene include any portions of the known exons . In addition, exon-intron boundaries are potentially useful targets for antisense inhibition of VEGF expression. One useful targeted region is around bases 58 to 90.
- the nucleotide sequences of some representative, non-limiting oligonucleotides specific for human VEGF have SEQ ID NOS:2-16.
- the oligonucleotides of the invention are composed of ribonucleotides, deoxyribonucleotides, or a combination of both, with the 5 ' end of one nucleotide and the 3 ' end of another nucleotide being covalently linked. These oligonucleotides are at least 14 nucleotides in length, but are preferably 15 to 30 nucleotides long, with 16 to 29mers being the most common.
- oligonucleotides can be prepared by the art recognized methods such as phosphoramidate or H-phosphonate chemistry which can be carried out manually or by an automated synthesizer as described in Uhlmann et al . ( Chem. Rev. (1990) 90:534-583) and Agra al ( Trends Biotechn ⁇ l. ( 1992) 10 :152-158) .
- the oligonucleotides of the invention may also be modified in a number of ways without compromising their ability to hybridize to VEGF mRNA.
- the oligonucleotides may contain at least one or a combination of other than phosphodiester internucleotide linkages between the 5 ' end of one nucleotide and the 3 ' end of another nucleotide in which the 5 ' nucleotide phosphodiester linkage has been replaced with any number of chemical groups .
- Examples of such chemical groups include alkylphosphonates, phosphorothioates, phosphorodithioates, alkylphosphonothioates, phosphoramidates, phosphate esters, carbamates, acetamidate, carboxymethyl esters, carbonates, and phosphate triesters.
- US Patent No. 5,149,797 describes traditional chimeric oligonucleotides having a phosphorothioate core region interposed between methylphosphonate or phosphoramidate flanking regions.
- No. (47508-559) filed on August 9, 1995 discloses "inverted" chimeric oligonucleotides comprising one or more nonionic oligonucleotide region (e.g. alkylphosphonate and/or phosphoramidate and/or phosphotriester internucleoside linkage) flanked by one or more region of oligonucleotide phosphorothioate.
- oligonucleotides with modified internucleotide linkages can be prepared according to known methods (see, e.g., Goodchild (1990) Bioconjugate Chem. 2:165-187; Agrawal et al . ,
- the phosphorothioate linkages may be mixed Rp and Sp enantiomers, or they may be stereoregular or substantially stereoregular in either Rp or Sp form (see Iyer et al . (1995) Tetrahedron Asymmetry 6:1051-1054) .
- Oligonucleotides with phosphorothioate linkages can be prepared using methods well known in the field such as phosphoramidite (see, e.g., Agrawal et al . (1988) Proc. Natl. Acad. Sci. (USA ) 85:7079-7083) . or by H- phosphonate (see, e.g., Froehler (1986) Tetrahedron Lett. 27:5575-5578) chemistry.
- the synthetic methods described in Bergot et al . J. Clwomatog. (1992) 559:35-42) can also be used.
- Oligonucleotides which are self-stabilized are also considered to be modified oligonucleotides useful in the methods of the invention (Tang et al . (1993) Nucleic Acids Res. 20:2729-2735) . These oligonucleotides comprise two regions: a target hybridizing region; and a self-complementary region having an oligonucleotide sequence complementary to a nucleic acid sequence that is within the self- stabilized oligonucleotide.
- modifications include those which are internal or at the end(s) of the oligonucleotide molecule and include additions to the molecule of the internucleoside phosphate linkages, such as cholesteryl or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the genome.
- cholesteryl or diamine compounds with varying numbers of carbon residues between the amino groups and terminal ribose, deoxyribose and phosphate modifications which cleave, or crosslink to the opposite chains or to associated enzymes or other proteins which bind to the genome.
- modified oligonucleotides include oligonucleotides with a modified base and/or sugar such as arabinose instead of ribose, or a 3 ' , 5 ' - substituted oligonucleotide having a sugar which, at both its 3 ' and 5 ' positions is attached to a chemical group other than a hydroxyl group (at its 3' position) and other than a phosphate group (at its 5 ' position) .
- modifications to sugars include modifications to the 2 ' position of the ribose moiety which include but are not limited to 2 ' -O-substituted with an -O- lower alkyl group containing 1-6 saturated or unsaturated carbon atoms, or with an -O-aryl, or allyl group having 2-6 carbon atoms wherein such -O-alkyl, aryl or allyl group may be unsubstituted or may be substituted, (e.g., with halo, hydroxy, trifluoromethyl cyano, nitro acyl acyloxy, alkoxy, carboxy, carbalkoxyl, or amino groups) , or with an amino, or halo group.
- Application Serial No. (47508-559) discloses an "inverted" hybrid oligonucleotide which includes an oligonucleotide comprising a 2 ' -O-substituted (or 2' OH, unsubstituted) RNA region which is in between two oligodeoxyribonucleotide regions, a structure that "inverted relative to the "traditional" hybrid oligonucleotides .
- Nonlimiting examples of particularly useful oligonucleotides of the invention have 2 ' -O-alkylated ribonucleotides at their 3 ' , 5 1 , or 3 ' and 5' termini, with at least four or five contiguous nucleotides being so modified.
- Non-limiting examples of 2 ' -O-alkylated groups include 2 '-0-methyl, 2 '-0-ethyl, 2 ' -O- propyl, and 2 ' -O-butyls .
- modified oligonucleotides are capped with a nuclease resistance-conferring bulky substituent at their 3 ' and/or 5 1 end(s) , or have a substitution in one nonbridging oxygen per nucleotide.
- Such modifications can be at some or all of the internucleoside linkages, as well as at either or both ends of the oligonucleotide and/or in the interior of the molecule.
- H-Z2 90-62 GGCTCCAATGCACCCAAGACAGCAGAAAG 11
- H-Z3 90-62 GGCTCCAATGCACCCAAGACAGCAGAAAG 11
- H-Z6 90-62 GGCTCCAATGCACCCAAGACAGCAGAAAG 11
- H-Z9 90-62 GGCTCCAATGCACCCAAGACAGCAGAAAG 11
- H-3D1 80-63 CACCCAAGACAGCAGAAA 12
- H-3D9 80-63 CACCCAAGACAGCAGAAA 12
- H-3D10 80-63 CACCCAAGACAGCAGAAA 12
- H-3E1 80-64 CACCCAAGACAGCAGAA 13
- H-3E9 80-64 CACCCAAGACAGCAGAA 13
- H-3E10 80-64 CACCCAAGACAGCAGAA 13
- H-3F9 80-65 CACCCAAGACAGCAGA 14 H-3F10 80-65 CACCCAAGACAGCAGA 14
- nucleotides bolded in the oligonucleotides above are 2 ' -0-alkylated, and all of the nucleotides are linked via non- phosphodiester internucleotide linkages such as phosphorothioates .
- nucleotides can be covalently linked using art-recognized techniques such as phosphoramidate, H-phosphonate chemistry, or methylphosphoramidate chemistry (see, e.g., Uhlmann et al. (1990) Chem. Rev. 90:543-584; Agrawal et al . (1987) Tetrahedron. Lett. 28 : (31) : 3539-3542 ) ; Caruthers et al. (1987) Meth. Enzy mol. 154:287-313; U.S. Patent
- Oligomeric phosphorothioate analogs can be prepared using methods well known in the field such as methoxyphosphoramidite (see, e.g.,
- the synthetic antisense oligonucleotides of the invention in the form of a therapeutic formulation are useful in treating diseases, and disorders, and conditions associated with angiogenesis and neovascularization including, but not limited to, retinal neovascularization, tumor growth, and wound healing.
- a therapeutic amount of a synthetic oligonucleotide of the invention and effective in inhibiting the expression of vascular endothelial growth factor is administered to a cell.
- This cell may be part of a cell culture, a neovascularized tissue culture, or may be part or the whole body of an animal such as a human or other mammal .
- Administration may be bolus, intermittent, or continuous, depending on the condition and response, as determined by those with skill in the art.
- the oligonucleotide is administered locally (e.g., intraocularly or interlesionally) and/or systemically.
- local administration refers to delivery to a defined area or region of the body, while the term “systemic administration is meant to encompass delivery to the whole organism by oral ingestion, or by intramuscular, intravenous, subcutaneous, or intraperitoneal injection.
- ROP retinopathy of prematurity
- diabetic retinopathy diabetic retinopathy
- age- related macular degeneration sickle cell retinopathy
- neovascular glaucoma retinal vein occlusion
- retinal vein occlusion retinal vein occlusion
- the synthetic oligonucleotides of the invention may be used as part of a pharmaceutical composition when combined with a physiologically and/or pharmaceutically acceptable carrier.
- a physiologically and/or pharmaceutically acceptable carrier The characteristics of the carrier will depend on the route of administration.
- Such a composition may contain, in addition to the synthetic oligonucleotide and carrier, diluents, fillers, salts, buffers, stabilizers, solubilizers, and other materials well known in the art.
- the pharmaceutical composition of the invention may also contain other active factors and/or agents which enhance inhibition of VEGF expression or which will reduce neovascularization.
- combinations of synthetic oligonucleotides, each of which is directed to different regions of the VEGF mRNA may be used in the pharmaceutical compositions of the invention.
- the pharmaceutical composition of the invention may further contain nucleotide analogs such as azidothymidine, dideoxycytidine, dideosyinosine, and the like.
- nucleotide analogs such as azidothymidine, dideoxycytidine, dideosyinosine, and the like.
- additional factors and/or agents may be included in the pharmaceutical composition to produce a synergistic effect with the synthetic oligonucleotide of the invention, or to minimize side-effects caused by the synthetic oligonucleotide of the invention.
- the synthetic oligonucleotide of the invention may be included in formulations of a particular anti-VEGF or anti-neovascularization factor and/or agent to minimize side effects of the anti-VEGF factor and/or agent.
- the pharmaceutical composition of the invention may be in the form of a liposome in which the synthetic oligonucleotides of the invention is combined, in addition to other pharmaceutically acceptable carriers, with amphipathic agents such as lipids which exist in aggregated form as micelles, insoluble monolayers, liquid crystals, or lamellar layers which are in aqueous solution.
- Suitable lipids for liposomal formulation include, without limitation, monoglycerides, diglycerides, sulfatides, lysolecithin, phospholipids, saponin, bile acids, and the like.
- One particularly useful lipid carrier is lipofectin. Preparation of such liposomal formulations is within the level of skill in the art, as disclosed, for example, in U.S. Patent No. 4,235,871; U.S. Patent No.
- the pharmaceutical composition of the invention may further include compounds such as cyclodextrins and the like which enhance delivery of oligonucleotides into cells, as described by Zhao et al . (in press) , or slow release polymers.
- the term "therapeutically effective amount” means the total amount of each active component of the pharmaceutical composition or method that is sufficient to show a meaningful patient benefit, i.e., healing of chronic conditions characterized by neovascularization or a reduction m neovascularization, itself, or m an increase m rate of healing of such conditions
- a meaningful patient benefit i.e., healing of chronic conditions characterized by neovascularization or a reduction m neovascularization, itself, or m an increase m rate of healing of such conditions
- the term refers to that ingredient alone
- the term refers to combined amounts of the active ingredients that result in the therapeutic effect, whether administered combination, serially or simultaneously
- a therapeutically effective amount of one, two, or more of the synthetic oligonucleotides of the invention is administered to a subject afflicted with a disease or disorder related to neovascularization, or to a tissue which has been neovascularized
- the synthetic oligonucleotide of the invention may be administered in accordance with the method of the invention either alone of in combination with other known therapies for neovascularization
- the synthetic oligonucleotide of the invention may be administered either simultaneously w th the other treatment (s) , or sequentially If administered sequentially, the attending physician will decide on the appropriate sequence of administering the synthetic oligonucleotide of the invention m combination with the other therapy
- Administration of the synthetic oligonucleotide of the invention used m the pharmaceutical composition or to practice the method of the present invention can be carried out in a variety of conventional ways, such as intraocular, oral ingestion, inhalation, or cutaneous, subcutaneous, intramuscular, or intravenous injection.
- the synthetic oligonucleotide When a therapeutically effective amount of synthetic oligonucleotide of the invention is administered orally, the synthetic oligonucleotide will be in the form of a tablet, capsule, powder, solution or elixir.
- the pharmaceutical composition of the invention may additionally contain a solid carrier such as a gelatin or an adjuvant.
- the tablet, capsule, and powder contain from about 5 to 95% synthetic oligonucleotide and preferably from about 25 to 90% synthetic oligonucleotide.
- a liquid carrier such as water, petroleum, oils of animal or plant origin such as peanut oil, mineral oil, soybean oil, sesame oil, or synthetic oils may be added.
- the liquid form of the pharmaceutical composition may further contain physiological saline solution, dextrose or other saccharide solution, or glycols such as ethylene glycol, propylene glycol or polyethylene glycol.
- the pharmaceutical composition When administered in liquid form, contains from about 0.5 to 90% by weight of the synthetic oligonucleotide and preferably from about 1 to 50% synthetic oligonucleotide.
- the synthetic oligonucleotide of the invention When a therapeutically effective amount of synthetic oligonucleotide of the invention is administered by intravenous, subcutaneous, intramuscular, intraocular, or intraperitoneal injection, the synthetic oligonucleotide will be in the form of a pyrogen-free, parenterally acceptable aqueous solution.
- parenterally acceptable solutions having due regard to pH, isotonicity, stability, and the like, is within the skill in the art.
- a preferred pharmaceutical composition for intravenous, subcutaneous, intramuscular, intraperitoneal, or intraocular injection should contain, in addition to the synthetic oligonucleotide, an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
- an isotonic vehicle such as Sodium Chloride Injection, Ringer's Injection, Dextrose Injection, Dextrose and Sodium Chloride Injection, Lactated Ringer's Injection, or other vehicle as known in the art.
- the pharmaceutical composition of the present invention may also contain stabilizers, preservatives, buffers, antioxidants, or other additives known to those of skill in the art.
- the amount of synthetic oligonucleotide in the pharmaceutical composition of the present invention will depend upon the nature and severity of the condition being treated, and on the nature of prior treatments which the patent has undergone. Ultimately, the attending physician will decide the amount of synthetic oligonucleotide with which to treat each individual patient. Initially, the attending physician will administer low doses of the synthetic oligonucleotide and observe the patient's response. Larger doses of synthetic oligonucleotide may be administered until the optimal therapeutic effect is obtained for the patient, and at that point the dosage is not increased further. It is contemplated that the various pharmaceutical compositions used to practice the method of the present invention should contain about 10 ⁇ g to about 20 mg of synthetic oligonucleotide per kg body or organ weight.
- the duration of intravenous therapy using the pharmaceutical composition of the present invention will vary, depending on the severity of the disease being treated and the condition and potential idiosyncratic response of each individual patient . Ultimately the attending physician will decide on the appropriate duration of intravenous therapy using the pharmaceutical composition of the present invention.
- Proliferative retinopathy can reach a threshold in a matter of days as seen in ROP, some cases of diabetic retinopathy, and neovascular glaucoma. Premature infants are at risk for neovascularization around what would be 35 weeks gestation, a few weeks after birth, and will remain at risk for a short period of time until the retina becomes vascularized. Diabetic retinopathy can be acute but may also smolder in the proliferative phase for considerably longer. Diabetic retinopathy will eventually become quiescent as the vasoproliferative signal diminishes with neovascularization or destruction of the retina.
- Intravitreal injections of oligonucleotides against VEGF can be an effective means of inhibiting retinal neovascularization in an acute situation.
- systemic delivery intraperitoneal, intramuscular, subcutaneous, intravenous either with carriers such as saline, slow release polymers, or liposomes should be considered.
- oligonucleotides may be preferable. Since the disease process concerns vessels which are abnormal and leaky, the problem of passage through the blood brain barrier may not be a problem. Therefore, systemic delivery may prove efficacious.
- the frequency of injections is from continuous infusion to once a month, depending on the disease process and the biological half life of the oligonucleotides.
- antisense oligonucleotides specific for VEGF are useful in determining the role of this cytokine in processes where neovascularization is involved.
- this technology is useful in in vitro systems which mimic blood vessel formation and permeability, and in in vivo system models of neovascularization, such as the murine model described below.
- Oligonucleotides of the invention are also useful in a method of reducing the expression of VEGF.
- the target VEGF expression can be in vitro or in any cell which expresses VEGF.
- nucleic acid specific for VEGF is contacted with an oligonucleotide of the invention such that transcription of the nucleic acid to mRNA and/or protein is reduced or inhibited.
- That oligonucleotides of the invention can inhibit VEGF expression at the protein level can be demonstrated using an ELISA which specifically detects human VEGF and a VEGF-expressing cell line such as a human glioblastoma (e.g., U373 ATCC Ac. no. HTB17 , American Type Culture Collection, Rockville, MD) or a human melanoma (e.g., SK-MEL- 2, ATCC Ac. no. HTB68, American Type Culture Collection, Rockville, MD; or M21) .
- a human glioblastoma e.g., U373 ATCC Ac. no. HTB17 , American Type Culture Collection, Rockville, MD
- a human melanoma e.g., SK-MEL- 2, ATCC Ac. no. HTB68, American Type Culture Collection, Rockville, MD; or M21
- FIGS. 2, 3, and 4 a human glioblastoma cell line U373 and a human melanoma cell lme M21 were treated with VEGF- specific oligonucleotides of the invention, these cells stop expressing VEGF a sequence-specific manner, as shown m FIGS. 2, 3, and 4, and in FIG. 5, respectively.
- FIG 6 demonstrates that modification of the oligonucleotides does not reduce their inhibitory activity.
- Oligonucleotides of the invention also reduced VEGF mRNA expression, as demonstrated by the Northern analyses described in EXAMPLE 4 below
- VEGF ' s role in tumor formation in vivo can be demonstrated using an athymic mouse injected with as an animal model. M21 cells are known to generate palpable tumors in mice m about 1 to 1.5 weeks. Alternately, a U373 cell line which has been passed through an athymic mouse the presence of Engelbreth Holm Swarm (EMS) tumor matrix (Matrigel 7 *, Collaborative Research, Waltham, MA) may be used.
- EMS Engelbreth Holm Swarm
- mice When mice are injected with VEGF-specific oligonucleotides of the invention, there will be a reduction in tumor weight and volume if VEGF expression is reduced by oligonucleotides or pharmaceutical formulations of the invention.
- VEGF plays a role m retinal neovascularization
- VEGF vascular endothelial growth factor
- Three independent experiments were performed using antisense oligonucleotides specific for VEGF (JG-3 (SEQ ID NO: 17), JG-4, (SEQ ID NO:18) , and Vm (SEQ ID NO: 19) , and a corresponding sense oligonucleotide (V2 (SEQ ID NO:20) .
- These oligonucleotides were designed using the known nucleic sequence of murine VEGF (Claffee et al . (1992) J. Biol. Chem. 267:16317-16322) .
- the sequence of the Vm oligonucleotide is targeted to the sequence surrounding the translational TGA stop site (TGA) .
- the sequence of JG-4 is targeted to the sequence 5 ' to and containing the ATG of the translational start site of the murine VEGF molecule.
- the sequence of JG-3 is targeted to the 5' untranslated region, and the V2 sense sequence is targeted to the sequence surrounding the translational start site (ATG) .
- Human VEGF cDNA is transcribed in vitro using an in vitro eucaryotic transcription kit (Stratagene, La Jolla, CA) .
- the RNA is labelled with 32 P using T-4 polynucleotide kinase as described by (Sambrook et al . ( 1989 ) Molecular Cloning; a Laboratory Manual , Cold
- RNA-DNA duplexes RNA-DNA duplexes
- RNase H an enzyme which cleaves RNA-DNA duplexes
- Cleavage patterns are analyzed on a 6% polyacrylamide urea gel. The specific location of the cleaved fragments is determined using a human VEGF sequence ladder (Sequenase Kit, United States Biochemical, Cleveland, OH) .
- Oligonucleotides having sequences complementary to VEGF nucleic acid determined as described above were synthesized on a Pharmacia Gene Assembler series synthesizer using the phosphoramidite procedure (see, e.g., Uhlmann et al. ( Chem. Rev. (1990) 90:534-583; Agrawal (1992) Trends in Biotech. 10:152-158; Agrawal et al. (1995) Curr. Opin. Biotechnol. 6:12-19) . Following assembly and deprotection, oligonucleotides were ethanol precipitated twice, dried, and suspended in phosphate-buffered saline (PBS) at the desired concentration.
- PBS phosphate-buffered saline
- oligonucleotide purity was tested by capillary gel electrophoreses and ion exchange HPLC. Endotoxin levels in the oligonucleotide preparation was determined using the Luminous Amebocyte Assay (Bang (1953) Biol. Bull. (Woods Hole, MA) 105:361-362) .
- DME glucose
- 2 mM glutamate Mediatech, Washington, DC
- penicillin/streptomycin 100 IU/MI/100 mcg/ml, Mediatech, Washington, DC
- the cells were cultured at 37°C under 10% C0 2 .
- the cells were plated in 96 well tissue culture dishes (Costar Corp., Cambridge, MA) and maintained as above.
- the cells were placed under anoxic conditions for 18-20 hours using an anaerobic chamber (BBL Gas Pak, Cockeysville, MD) or in the presence of 250 ⁇ M CoCl 2 .
- U373 glioblastoma cells were plated in a 96 well tissue culture dish and treated overnight with varying concentrations of antisense oligonucleotides against human VEGF in the presence of 5 ⁇ g/ml lipofectin. The cells were refed after 7 to 12 hours with fresh media and allowed to recover for 5 to 7 hours. The dishes were placed under hypoxic conditions for 18 to 20 hours using an anaerobic chamber (Gas Pac,
- Cockeysville, MD Cockeysville, MD
- 250 ⁇ M CoCl 2 Cells maintained under normoxic conditions served as uninduced controls .
- the media was analyzed using the antigen capture ELISA assay described below (approximately 24 hours post treatment) .
- the culture medium from the cells described in EXAMPLE 2 was analyzed for VEGF protein as follows. 96-well plates (Maxizorb ELISA Nunc A/S, Camstrup, Denmark) were treated overnight at 4°C with 100 ⁇ l/well of the capture antibody, a monoclonal antibody against human VEGF (R&D Systems, Minneapolis, MN, 2.5 ⁇ g/ml in IX PBS) . The wells were washed three times with lx PBS/0.05% Tween-20 (United States Biochemical, Cleveland, OH) using a plate washer (Dynatech, Gurnsey Channel Islands) .
- Non-specific binding sites in the wells were blocked by adding 2% normal human serum (200 ⁇ l) and incubating the plate at 37°C for 2 hours. This blocking solution was removed and 200 ⁇ l conditioned medium containing human VEGF added to each well and incubated at 37°C for 2 to 3 hours or overnight at 4°C. The plates were washed as described above. 100 ⁇ l of the primary antibody (618/619, 2 ⁇ g/ml in normal human serum) was added to each well and incubated at 37°C for 1 to 2 hours. The primary antibody was an affinity purified rabbit anti- human VEGF polyclonal) . The plates were washed as described above.
- Northern blotting was performed according to the methods of Sambrook et al . ( Molecular Cloning: Laboratory Manual , Cold Spring Harbor Laboratory Press, NY) (1989) Vol. 1, pp. 7.38) or Arcellana-Panlilio et al . ( Meth. Enz.
- RNA expression was reduced in the presence of VEGF-specific oligonucleotides of the invention, and is not significantly affected by the presence of control sense oligonucleotide.
- U373 glioblastoma cells were treated with 0.5 ⁇ M antisense phosphorothioate oligodeoxynucleotide (H-3, SEQ ID NO : 1 ) or control (H3-sense phosphorothioate oligonucleotide; SEQ ID NO: 21) for 7 hours in the presence of 5 ⁇ g/ ⁇ l
- Lipofectin (Gibco-BRL, Gaithersburg, MD) . 1 x 10 6 oligonucleotide-treated cells were mixed with 250 ⁇ l Matrigel 1 * (Collaborative Research, Waltham, MA; 10-12 mg/ml) and injected subcutaneously into 6-8 week old athymic mice (about 20 g) (Charles River Laboratories, Wilmington, MA) on both the left and right sides. These cells respond to hypoxia and express increased levels of VEGF. The mice were maintained ad libitum and sacrificed 8 days post injection. The skin was dissected to expose the Matrigel pellet. Gross photography of the surrounding blood vessels was performed with a Zeiss Macroscope. The Matrigel plugs were removed and fixed in formalin for paraffin embedding and histological analysis. Tissue sections were stained with hematoxylin and eosin for quantitation of blood vessel growth into the Matrigel plug.
- Matrigel plugs combined with U373 glioblastoma cells contained visible hemhorraging . In addition, the capillary bed surrounding the plug was more dense and the blood vessels were more tortuous. Athymic mice injected with Matrigel plugs combined with antisense oligonucleotide- treated cells generated less angiogenesis than the mice injected with Matrigel plugs and either untreated cells or cells pretreated with the control oligonucleotide. Matrigel plugs containing antisense treated cells also had less visible hemhorraging. The results suggest that antisense oligonucleotide treatment inhibit VEGF- induced angiogenesis.
- Athymic mice 6 week old athymic mice (about 20 g) are purchased from Charles River Laboratories.
- Human melanoma M21 cells or human glioblastoma U373 cells which have been passaged through athymic mice in the presence of Matrigel are injected subcutaneously (2-20 x IO 6 ) into the flank of athymic mice. Palpable tumors are generated in 1- 2 weeks .
- Subcutaneous antisense or sense control oligonucleotide injections begin one day following the injection of the tumor cells. The concentration of oligonucleotide is determined and ranges between 5 and 50 mg/kg. Animals are then injected over a period of three weeks. They are then sacrificed and the tumors removed. Tumors are analyzed initially for weight and volume. In addition, analysis includes sectioning and staining for VEGF/VPF protein using an anti- human
- VEGF/VPF monoclonal antibody R&D Systems, Minneapolis, MN
- VEGF/VPF RNA using in situ hybridization techniques. Mice injected with antisense oligonucleotides of the invention are expected to have smaller tumors than those injected with vehicle or the control.
- JG-3 (SEQ ID NO: 17)
- JG-4 (SEQ ID NO:18)
- Vm (SEQ ID NO: 19)
- V2 (SEQ ID NO:20)
- mice Seven day postnatal mice (P7, C57bl/6J, (Children's Hospital Breeding Facilities, Boston, MA) were exposed to 5 days of hyperoxic conditions (75 +/- 2%) oxygen in a sealed incubator connected to a Bird 3-M oxygen blender (flow rate: 1.5 liters/minute; Bird, Palm Springs, CA) .
- the oxygen concentration was monitored by means of an oxygen analyzer (Beckman, Model D2, Irvine, CA) .
- the mice were returned to room air. Maximal retinal neovascularization was observed 5 days after return to room air (P17) .
- P21 the level of retinal neovascularization was just beginning to regress.
- antisense oligonucleotides were injected into the vitreous with a Hamilton syringe and a 33 gauge needle (Hamilton Company, Reno, NV) .
- the animals were anesthetized for the procedure with Avertin ip.
- the mice were given a single injection of antisense oligonucleotides (or sense or non-sense controls) at P12 achieving a final concentration of approximately 30-50 ⁇ M.
- the animals were sacrificed at P17 with tribromoethanol ip (0.1 ml/g body weight) and cervical dislocation.
- the eyes were enucleated, fixed in 4% paraformaldehyde, and embedded in paraffin. Serial sections of the whole eyes were cut sagittally, through the cornea, and parallel to the optic nerve. The sections were stained with hematoxylin and periodic acid-Schiff (PAS) stain. The extent of neovascularization in the treated eyes was determined by counting endothelial cell nuclei extending past the internal limiting membrane into the vitreous. Nuclei from new vessels and vessel profiles could be distinguished from other structures in the retina and counted in cross-section with light microscopy. Additional eyes were sectioned and examined by in situ hybridization to a VEGF probe.
- PAS periodic acid-Schiff
- mice were perfused with a 50 mg/ml solution of high molecular weight fluorescein-dextran (Sigma Chemical Company, St. Louis, MO) in 4% paraformaldehyde.
- the eyes were enucleated, fixed in paraformaldehyde, and flat- mounted with glycerol-gelati .
- the flat-mounted retinas were viewed and photographed by fluorescence microscopy using an Olympus BX60 fluorescence microscope (Olympus America Corp., Bellingham, MA) .
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA/RNA
- HYPOTHETICAL NO
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE YES
- MOLECULE TYPE cDNA
- HYPOTHETICAL NO
- ANTI-SENSE NO
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU12793/97A AU1279397A (en) | 1995-12-08 | 1996-12-05 | Modified vegf antisense oligonucleotides |
JP9522098A JP2000501941A (en) | 1995-12-08 | 1996-12-05 | Modified VEGF antisense oligonucleotide |
EP96943587A EP0865489A1 (en) | 1995-12-08 | 1996-12-05 | Modified vegf antisense oligonucleotides |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/569,926 | 1995-12-08 | ||
US08/569,926 US5641756A (en) | 1993-07-27 | 1995-12-08 | Modified VEGF oligonucleotides |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1997021808A1 true WO1997021808A1 (en) | 1997-06-19 |
Family
ID=24277485
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1996/019320 WO1997021808A1 (en) | 1995-12-08 | 1996-12-05 | Modified vegf antisense oligonucleotides |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0865489A1 (en) |
JP (1) | JP2000501941A (en) |
AU (1) | AU1279397A (en) |
CA (1) | CA2239991A1 (en) |
WO (1) | WO1997021808A1 (en) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2793798A1 (en) * | 1999-05-21 | 2000-11-24 | Inst Nat Sante Rech Med | Antisense oligonucleotide, useful for treating e.g. cancer or restenosis, is directed against the translational elongation factor gene |
WO2001052904A2 (en) * | 2000-01-19 | 2001-07-26 | Gill Parkash S | Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
GB2406569A (en) * | 2002-02-20 | 2005-04-06 | Sirna Therapeutics Inc | Double-stranded, short interfering nucleic aicd (siNA) molecules |
US7087580B2 (en) | 1998-04-23 | 2006-08-08 | Genesense Technologies, Inc. | Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth |
US7176304B2 (en) | 2002-02-20 | 2007-02-13 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
AU2006233188B2 (en) * | 2000-01-19 | 2008-01-24 | Parkash S Gill | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
US8546349B2 (en) | 2010-07-28 | 2013-10-01 | Thermo Fisher Scientific Biosciences Inc. | siRNA targeting VEGFA and methods for treatment in vivo |
US8575329B2 (en) | 2002-11-14 | 2013-11-05 | Thermo Fisher Scientific Biosciences Inc. | siRNA targeting kinase insert domain receptor (KDR) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004142A2 (en) * | 1993-07-27 | 1995-02-09 | Hybridon, Inc. | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
WO1996023065A2 (en) * | 1995-01-26 | 1996-08-01 | Hybridon, Inc. | Inhibition of neovascularization using vegf-specific oligonucleotides |
WO1996027006A2 (en) * | 1995-03-02 | 1996-09-06 | Hybridon, Inc. | Human vegf-specific antisense oligonucleotides |
-
1996
- 1996-12-05 CA CA002239991A patent/CA2239991A1/en not_active Abandoned
- 1996-12-05 JP JP9522098A patent/JP2000501941A/en active Pending
- 1996-12-05 AU AU12793/97A patent/AU1279397A/en not_active Abandoned
- 1996-12-05 WO PCT/US1996/019320 patent/WO1997021808A1/en not_active Application Discontinuation
- 1996-12-05 EP EP96943587A patent/EP0865489A1/en not_active Withdrawn
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1995004142A2 (en) * | 1993-07-27 | 1995-02-09 | Hybridon, Inc. | Antisense oligonucleotide inhibition of vascular endothelial growth factor expression |
WO1996023065A2 (en) * | 1995-01-26 | 1996-08-01 | Hybridon, Inc. | Inhibition of neovascularization using vegf-specific oligonucleotides |
WO1996027006A2 (en) * | 1995-03-02 | 1996-09-06 | Hybridon, Inc. | Human vegf-specific antisense oligonucleotides |
Non-Patent Citations (6)
Title |
---|
1ST INTERNATIONAL ANTISENSE CONFERENCE IN JAPAN, 4 December 1994 (1994-12-04) - 7 December 1994 (1994-12-07) * |
ADAMIS, A. ET AL.: "Synthesis and secretion of vascular permeability factor/vascular endothelial growth factor by human retinal pigment epithelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, vol. 193, 15 June 1993 (1993-06-15), ORLANDO, FL US, pages 631 - 638, XP002007152 * |
MONIA B P ET AL: "EVALUATION OF 2'-MODIFIED OLIGONUCLEOTIDES CONTAINING 2'-DEOXY GAPS AS ANTISENSE INHIBITORS OF GENE EXPRESSION", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 268, no. 19, 5 July 1993 (1993-07-05), pages 14514 - 14522, XP000576145 * |
TISCHER, E. ET AL.: "The human gene for vascular endothelial growth factor", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, 25 June 1991 (1991-06-25), MD US, pages 11947 - 11954, XP002007151 * |
UCHIDA, K. ET AL.: "Selection of antisense oligodeoxyribonucleotides that inhibit VEGF/VPF expression in a cell-free system", ANTISENSE RES.DEV. 5 (SPRING 95);87-8;OP-10, XP002006442 * |
UHLMANN E ET AL: "ANTISENSE OLIGONUCLEOTIDES: A NEW THERAPEUTIC PRINCIPLE", CHEMICAL REVIEWS, vol. 90, no. 4, 1 June 1990 (1990-06-01), pages 543 - 584, XP000141412 * |
Cited By (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7087580B2 (en) | 1998-04-23 | 2006-08-08 | Genesense Technologies, Inc. | Neuropilin antisense oligonucleotide sequences and methods of using same to modulate cell growth |
WO2000071708A2 (en) * | 1999-05-21 | 2000-11-30 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Use of ef-ts for treating smooth muscle cell hyperplasia |
WO2000071708A3 (en) * | 1999-05-21 | 2001-03-01 | Inst Nat Sante Rech Med | Use of ef-ts for treating smooth muscle cell hyperplasia |
FR2793798A1 (en) * | 1999-05-21 | 2000-11-24 | Inst Nat Sante Rech Med | Antisense oligonucleotide, useful for treating e.g. cancer or restenosis, is directed against the translational elongation factor gene |
AU2006233188B2 (en) * | 2000-01-19 | 2008-01-24 | Parkash S Gill | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
WO2001052904A2 (en) * | 2000-01-19 | 2001-07-26 | Gill Parkash S | Pharmaceutical compositions and methods of treatment based on vegf antisense oligonucleotides |
WO2001052904A3 (en) * | 2000-01-19 | 2002-04-25 | Parkash S Gill | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
EP1564292A1 (en) * | 2000-01-19 | 2005-08-17 | Parkash S. Gill | Pharmaceutical compositions and methods of treatment based on VEGF antisense oligonucleotides |
US9994853B2 (en) | 2001-05-18 | 2018-06-12 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US9957517B2 (en) | 2002-02-20 | 2018-05-01 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9771588B2 (en) | 2002-02-20 | 2017-09-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10889815B2 (en) | 2002-02-20 | 2021-01-12 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10662428B2 (en) | 2002-02-20 | 2020-05-26 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10351852B2 (en) | 2002-02-20 | 2019-07-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US10000754B2 (en) | 2002-02-20 | 2018-06-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9181551B2 (en) | 2002-02-20 | 2015-11-10 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
GB2406569A (en) * | 2002-02-20 | 2005-04-06 | Sirna Therapeutics Inc | Double-stranded, short interfering nucleic aicd (siNA) molecules |
US9657294B2 (en) | 2002-02-20 | 2017-05-23 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9732344B2 (en) | 2002-02-20 | 2017-08-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US9738899B2 (en) | 2002-02-20 | 2017-08-22 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
US7176304B2 (en) | 2002-02-20 | 2007-02-13 | Mcswiggen James | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfering nucleic acid (siNA) |
GB2406569B (en) * | 2002-02-20 | 2005-07-20 | Sirna Therapeutics Inc | RNA interference mediated inhibition of vascular endothelial growth factor and vascular endothelial growth factor receptor gene expression using short interfe |
US8575329B2 (en) | 2002-11-14 | 2013-11-05 | Thermo Fisher Scientific Biosciences Inc. | siRNA targeting kinase insert domain receptor (KDR) |
EP2314691A3 (en) * | 2002-11-14 | 2012-01-18 | Dharmacon, Inc. | Fuctional and hyperfunctional siRNA |
US10508277B2 (en) | 2004-05-24 | 2019-12-17 | Sirna Therapeutics, Inc. | Chemically modified multifunctional short interfering nucleic acid molecules that mediate RNA interference |
US9150862B2 (en) | 2010-07-28 | 2015-10-06 | Thermo Fisher Scientific Inc. | siRNA targeting VEGFA and methods for treatment in vivo |
US8546349B2 (en) | 2010-07-28 | 2013-10-01 | Thermo Fisher Scientific Biosciences Inc. | siRNA targeting VEGFA and methods for treatment in vivo |
US9970005B2 (en) | 2010-10-29 | 2018-05-15 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US9260471B2 (en) | 2010-10-29 | 2016-02-16 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11193126B2 (en) | 2010-10-29 | 2021-12-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
US11932854B2 (en) | 2010-10-29 | 2024-03-19 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
Also Published As
Publication number | Publication date |
---|---|
AU1279397A (en) | 1997-07-03 |
CA2239991A1 (en) | 1997-06-19 |
JP2000501941A (en) | 2000-02-22 |
EP0865489A1 (en) | 1998-09-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5641756A (en) | Modified VEGF oligonucleotides | |
CA2210998C (en) | Inhibition of neovascularization using vegf-specific oligonucleotides | |
US5639872A (en) | Human VEGF-specific oligonucleotides | |
US6306829B1 (en) | Modified VEGF oligonucleotides for treatment of skin disorders | |
EP1340765A2 (en) | Inverted chimeric and hybrid oligonucleotides | |
EP0865489A1 (en) | Modified vegf antisense oligonucleotides | |
US5866699A (en) | Oligonucleotides with anti-MDR-1 gene activity | |
US20050222065A1 (en) | Vascular therapeutics | |
US5969117A (en) | Modified protein kinase a-specific oligonucleotide | |
WO1997011171A9 (en) | Modified protein kinase a-specific oligonucleotides and methods of their use | |
CA2214431C (en) | Human vegf-specific antisense oligonucleotides | |
US5789248A (en) | CAPL-specific oligonucleotides and method of inhibiting metastatic cancer | |
WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
EP1007656A1 (en) | Modified protein kinase a-specific oligonucleotides and methods of their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE FI GB GE HU IL IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG UZ VN AM AZ BY KG KZ MD RU TJ TM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 1997 522098 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1996943587 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2239991 Country of ref document: CA Ref country code: CA Ref document number: 2239991 Kind code of ref document: A Format of ref document f/p: F |
|
WWP | Wipo information: published in national office |
Ref document number: 1996943587 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1996943587 Country of ref document: EP |